Daiichi Sankyo Aims $500 Million Sales For Prasugrel By 2013
This article was originally published in PharmAsia News
Executive SummaryDaiichi Sankyo has established a priority for blood thinning agent Effient (prasugrel) and set a global sales goal of $500 million in three years. Launched last year in the U.S. and Europe, the potential blockbuster antiplatelet agent is co-promoted with Eli Lilly. Daiichi President Takashi Shoda disclosed that the two are exploring ways to further marketing efforts. Daiichi recently revealed a three-year mid-term business strategy, in which it plans to focus resources on expanding market shares for prasugrel, hoping to grow it as the first-in-class oral antiplatelet treatment. Meanwhile, for another potential oral Xa factor inhibitor DU-176b (edoxaban), Daiichi has decided to first launch it in the domestic market. (Click here for more - Japanese language
You may also be interested in...
Brands unfairly maligned by powerful influencers, strictly on behalf of paying competitors, could have occasion to broach the subject with the US Federal Trade Commission, which seeks comment on its “Endorsement Guides” in an increasingly complex and competitive, digitized advertising environment.
At least one FTC commissioner seems convinced that the agency’s Enforcement Guides are ripe for an update to address unscrupulous influencer marketing practices. Democrat Rohit Chopra proposes their codification into formal rules that would make violators liable for civil penalties and damages under FTC Act provisions.
The US agency has suspended all routine surveillance inspections in China through the end of March because of coronavirus fears, commissioner Stephen Hahn announced late on 14 February. Despite expecting medical product shortages, Hahn said the agency is being proactive: “We are not waiting for drug and device manufacturers to report shortages to us” before acting. The timing of Hahn’s statement – at 6 p.m. EST on a Friday, at the beginning of a three-day US holiday weekend – suggests he isn’t particularly excited to share the information.